JP7165410B2 - 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物 - Google Patents

組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物 Download PDF

Info

Publication number
JP7165410B2
JP7165410B2 JP2019530369A JP2019530369A JP7165410B2 JP 7165410 B2 JP7165410 B2 JP 7165410B2 JP 2019530369 A JP2019530369 A JP 2019530369A JP 2019530369 A JP2019530369 A JP 2019530369A JP 7165410 B2 JP7165410 B2 JP 7165410B2
Authority
JP
Japan
Prior art keywords
composition
raav
nucleic acid
promoter
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019530369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524890A5 (cg-RX-API-DMAC7.html
JP2019524890A (ja
Inventor
バートレット、ジェフリー、エス．
スティーブン シー． ギヴィッツァーニ，
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド filed Critical ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
Publication of JP2019524890A publication Critical patent/JP2019524890A/ja
Publication of JP2019524890A5 publication Critical patent/JP2019524890A5/ja
Priority to JP2022111264A priority Critical patent/JP7653150B2/ja
Application granted granted Critical
Publication of JP7165410B2 publication Critical patent/JP7165410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019530369A 2016-08-19 2017-08-18 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物 Active JP7165410B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022111264A JP7653150B2 (ja) 2016-08-19 2022-07-11 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377297P 2016-08-19 2016-08-19
US62/377,297 2016-08-19
PCT/US2017/047589 WO2018035451A1 (en) 2016-08-19 2017-08-18 Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022111264A Division JP7653150B2 (ja) 2016-08-19 2022-07-11 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2019524890A JP2019524890A (ja) 2019-09-05
JP2019524890A5 JP2019524890A5 (cg-RX-API-DMAC7.html) 2020-12-24
JP7165410B2 true JP7165410B2 (ja) 2022-11-04

Family

ID=61197123

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530369A Active JP7165410B2 (ja) 2016-08-19 2017-08-18 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
JP2022111264A Active JP7653150B2 (ja) 2016-08-19 2022-07-11 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022111264A Active JP7653150B2 (ja) 2016-08-19 2022-07-11 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物

Country Status (9)

Country Link
US (2) US11207382B2 (cg-RX-API-DMAC7.html)
EP (1) EP3500278B1 (cg-RX-API-DMAC7.html)
JP (2) JP7165410B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230130155A (cg-RX-API-DMAC7.html)
CN (1) CN109843306A (cg-RX-API-DMAC7.html)
AU (1) AU2017313844B2 (cg-RX-API-DMAC7.html)
CA (1) CA3073137A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982489T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018035451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207382B2 (en) 2016-08-19 2021-12-28 University Of Florida Research Foundation, Incorporated Compositions for treating conditions using recombinant self-complementary adeno-associated virus
AU2017371043B2 (en) * 2016-12-07 2022-12-15 University Of Florida Research Foundation, Incorporated IL-1Ra cDNAs
DK3740222T5 (da) 2018-01-17 2024-08-26 Meiragtx Uk Ltd Modificeret RAAV-capsidprotein til genterapi
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
KR20210126096A (ko) 2019-02-15 2021-10-19 상가모 테라퓨틱스, 인코포레이티드 재조합 aav를 제조하기 위한 조성물 및 방법
CA3146791A1 (en) * 2019-07-15 2021-01-21 Meiragtx Uk Ii Limited Modified aav capsid proteins for treatment of arthritic disease
WO2021138559A1 (en) * 2019-12-31 2021-07-08 Swanbio Therapeutics Limited Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
WO2025049993A1 (en) 2023-08-31 2025-03-06 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130217864A1 (en) 2010-10-20 2013-08-22 Handok Pharmaceuticals Co., Ltd. Human interleukin-1 receptor antagonist - hybrid fc fusion protein

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5747072A (en) 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
WO1995016353A1 (en) * 1993-12-14 1995-06-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Systemic gene treatment of connective tissue diseases
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU728220B2 (en) 1997-04-14 2001-01-04 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
ES2312344T3 (es) 1999-05-28 2009-03-01 Targeted Genetics Corporation Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf.
AU3459701A (en) 2000-01-26 2001-08-07 Chiron Corporation Recombinant aav packaging systems
CA2410828C (en) 2000-06-01 2012-01-24 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
DE10056210A1 (de) 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
WO2002062375A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
KR100472297B1 (ko) 2001-09-27 2005-03-07 주식회사 두산 리소인지질의 수용성 조성물
KR100471942B1 (ko) 2002-03-19 2005-03-09 주식회사 에스원 복합형 카드와 카드정보 등록 제어시스템
DE10318048A1 (de) 2003-04-17 2004-11-04 Axaron Bioscience Ag Nicht fluoreszierende, durch Proteolyse zur Fluoreszenz aktivierbare Reporterproteine und ihre Verwendung zur Detektion Protease-abhängiger Ereignisse
NZ545656A (en) 2003-09-01 2009-02-28 Amc Amsterdam AAV vectors for in vivo gene therapy of rheumatoid arthritis
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
FR2891544A1 (fr) 2005-09-30 2007-04-06 Genethon Ass Loi De 1901 Substrat proteique pour la detection de l'activite calpaine 3
WO2007112001A2 (en) 2006-03-23 2007-10-04 Caritas St. Elizabeth Medical Center Of Boston, Inc. Compositions and methods for treating myocardial infarction
EP2037943A4 (en) 2006-04-21 2010-03-31 Univ North Carolina TREATMENT OF BIND WEB DISEASES
US20080187576A1 (en) * 2006-06-16 2008-08-07 University Of Florida Research Foundation, Inc. Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors
US20080166762A1 (en) 2006-09-27 2008-07-10 Reliance Life Science Pvt.Ltd. HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS
US7452696B2 (en) 2006-10-27 2008-11-18 National Taiwan University Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo
JP5575486B2 (ja) 2007-01-18 2014-08-20 ユニヴァーシティ オブ ミズーリー−コロンビア 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
KR101667069B1 (ko) * 2008-11-17 2016-10-17 이노비오 파마수티컬즈, 인크. 플라비바이러스에 대한 면역반응을 유발하는 항원 및 이를 사용하는 방법
US9610363B2 (en) 2009-04-16 2017-04-04 President And Fellows Of Harvard College Methods for inhibiting starvation of a cell
BR112012007114A2 (pt) 2009-09-29 2016-07-05 Gilead Biologics Inc métodos e composições para tratamento da fibrose ocular
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
US8736207B2 (en) 2011-01-03 2014-05-27 General Electric Company Method and system for power conversion
CN103596591B (zh) 2011-02-08 2016-08-24 Abbvie公司 骨关节炎和疼痛的治疗
US20130021786A1 (en) 2011-07-21 2013-01-24 Noble Matthew D Utility bag lighting
ES2534782T3 (es) 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9254311B2 (en) * 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2660325A3 (en) 2012-05-02 2014-02-12 Christian Medical College AAV vectors and corresponding nucleotide sequences and methods
CN103509100B (zh) 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
US9624282B2 (en) 2012-11-26 2017-04-18 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
ES2802878T3 (es) 2013-01-25 2021-01-21 Baylor College Medicine Un sistema de administración y expresión de terapia génica adenoviral dependiente de linfocitos T colaboradores
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
CN105682674A (zh) 2013-04-17 2016-06-15 建新公司 用于治疗和预防黄斑变性的组合物和方法
DE102013215817A1 (de) 2013-08-09 2015-02-12 Universitätsklinikum Hamburg-Eppendorf Neue peptide mit spezifität für die lunge
ES2936220T3 (es) 2013-08-27 2023-03-15 Res Inst Nationwide Childrens Hospital Productos y métodos para el tratamiento de la esclerosis lateral amiotrófica
EP3068889B1 (en) 2013-09-26 2019-04-17 Universitat Autònoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
WO2015160893A1 (en) 2014-04-15 2015-10-22 Applied Genetic Technologies Corporation Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)
DE102014207498A1 (de) 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
IL248102B (en) 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
US11207382B2 (en) 2016-08-19 2021-12-28 University Of Florida Research Foundation, Incorporated Compositions for treating conditions using recombinant self-complementary adeno-associated virus
WO2018035457A1 (en) 2016-08-19 2018-02-22 Calimmune, Inc. Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
US20200318080A1 (en) 2016-08-19 2020-10-08 Colorado State University Research Foundation Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus
AU2017371043B2 (en) 2016-12-07 2022-12-15 University Of Florida Research Foundation, Incorporated IL-1Ra cDNAs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130217864A1 (en) 2010-10-20 2013-08-22 Handok Pharmaceuticals Co., Ltd. Human interleukin-1 receptor antagonist - hybrid fc fusion protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gene Therapy，2004年，vol.11，p.581-590
J Gene Med，2009年，vol.11, no.7，p.605-614
Molecular Therapy-Nucleic Acids，2013年，vol.2, e70，p.1-10

Also Published As

Publication number Publication date
US20190381140A1 (en) 2019-12-19
KR20230130155A (ko) 2023-09-11
US11207382B2 (en) 2021-12-28
JP7653150B2 (ja) 2025-03-28
EP3500278C0 (en) 2024-05-22
CA3073137A1 (en) 2018-02-22
EP3500278A1 (en) 2019-06-26
KR102759317B1 (ko) 2025-01-31
JP2022130745A (ja) 2022-09-06
WO2018035451A1 (en) 2018-02-22
EP3500278B1 (en) 2024-05-22
US20220175887A1 (en) 2022-06-09
EP3500278A4 (en) 2020-04-01
AU2017313844A1 (en) 2019-04-11
KR20190055086A (ko) 2019-05-22
AU2017313844B2 (en) 2023-10-12
JP2019524890A (ja) 2019-09-05
CN109843306A (zh) 2019-06-04
ES2982489T3 (es) 2024-10-16

Similar Documents

Publication Publication Date Title
JP7653150B2 (ja) 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
JP7629584B2 (ja) 哺乳動物の変形性関節症及び関連する関節症状の治療に有用なｈａｓ２及びルブリシンを含む骨保護遺伝子を発現する組換えａａｖベクター
Evans et al. Gene therapeutic approaches—transfer in vivo
Madry et al. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage
US20200318080A1 (en) Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus
Ratko et al. Clinical gene therapy for nonmalignant disease
US20210283222A1 (en) Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
KR20240063110A (ko) 치료제의 역행성 관상 정맥 또는 정맥동 투여
US20220403415A1 (en) Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same
Trippel et al. Gene therapy for articular cartilage repair
JP4863874B2 (ja) 関節リウマチのインビボ遺伝子治療のためのａａｖベクター
CN118871459A (zh) 新型蛋白质和核酸序列及其在预防和/或治疗先天性肌营养不良症中的用途
Ferreira et al. Advances in Gene Therapy for Respiratory and Renal Diseases
Ferreira et al. Journal of Stem Cell Research
Ghivizzani et al. Gene therapy for osteoarthritis
le Goff 031 Vegf 111 as a New Therapeutic Tool for Tendon Lesion
JP2020516644A (ja) 腱および靱帯の損傷に対するｖｅｇｆ遺伝子治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200817

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220711

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220825

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221017

R150 Certificate of patent or registration of utility model

Ref document number: 7165410

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250